What is the clinical evidence from this study?

Study design: Other. Population: Low-renin hypertension and primary aldosteronism (n=20). Intervention: Dopamine infusion vs. Baseline. Primary outcome: Plasma aldosterone concentration (ng/dl) in patients with zona glomerulosa hyperplasia (p=<0.01).

September 1, 1983Journal of Clinical InvestigationOpen Access

Aldosterone suppression with dopamine infusion in low-renin hypertension.

Q: What are the key findings of this study?

Dopamine infusion significantly suppressed plasma aldosterone concentrations from 16.4 ng/dl to 8.6 ng/dl in patients with zona glomerulosa hyperplasia, whereas it had no effect in normal-renin hypertensive patients.

View Full Paper

Ask AI

Bookmark

Key result

Dopamine infusion significantly suppressed plasma aldosterone concentrations from 16.4 ng/dl to 8.6 ng/dl in patients with zona glomerulosa hyperplasia, whereas it had no effect in normal-renin hypertensive patients.

Why the study?

Does dopamine receptor stimulation or blockade alter aldosterone secretion in different subtypes of hypertensive patients?

Population

20 hypertensive patients, including 7 with low-renin hypertension and abnormal aldosterone suppression with…

Comparison

Dopamine receptor stimulation with dopamine… vs Baseline measurements and comparisons across the…

Design

Cohort

Authors

OHO. B. HollandHoward Hughes Medical Institute CTCharlotte L ThomasRoyal Prince Alfred Hospital HBH BrownThe University of Texas Medical Branch at Galveston

Discussion

Member takes

Implication

Suggests dopaminergic aldosterone control in ZG hyperplasia; hypothesis-generating for subtype differentiation in low-renin hypertension.

Structured PICO

Does dopamine receptor stimulation or blockade alter aldosterone secretion in different subtypes of hypertensive patients?

Population

20 patients with low-renin hypertension, primary aldosteronism, or normal-renin hypertension underwent acute physiological testing to assess dopaminergic regulation of aldosterone secretion.

Intervention

Dopamine receptor stimulation with dopamine infusion and bromocriptine administration, and dopamine receptor blockade with metoclopramide.

Comparator

Baseline measurements (before intervention) and comparisons across the different hypertensive patient groups.

Outcome

Basal and adrenocorticotropic hormone (ACTH)-stimulated plasma aldosterone (PA), cortisol, renin activity, and potassium concentrations.surrogate

Main Result

Absolute Event Rate: 8.6% vs 16.4%

p-value: p=<0.01

A dopaminergic mechanism appears to play an important role in regulating aldosterone secretion in specific subsets of low-renin hypertensive patients, differentiating them from normal-renin hypertensives.

Limitations

Small sample size
Acute nature of the interventions
Inability to definitively distinguish between primary adrenal mechanisms and secondary phenomena

Cite This Study

Holland et al. (1983) studied Low-renin hypertension and primary aldosteronism (n=20). Dopamine infusion vs. Baseline was evaluated on Plasma aldosterone concentration (ng/dl) in patients with zona glomerulosa hyperplasia (p=<0.01). Dopamine infusion significantly suppressed plasma aldosterone concentrations from 16.4 ng/dl to 8.6 ng/dl in patients with zona glomerulosa hyperplasia, whereas it had no effect in normal-renin hypertensive patients.

synapsesocial.com/papers/6a238dbc55bd20cf6fa5fae7 https://doi.org/10.1172/jci111046

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Aldosterone suppression with dopamine infusion in low-renin hypertension.

Discussion

Member takes

Implication

Structured PICO

Main Result

Limitations

Cite This Study

Topics

Aldosterone suppression with dopamine infusion in low-renin hypertension.

Discussion

Member takes

Implication

Structured PICO

Main Result

Limitations

Cite This Study

Also Consider

Topics

Also Consider